We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced-Dose or Discontinuation of Bevacizumab Might Be Considered after Variceal Bleeding in Patients with Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab: Case Reports.
- Authors
Yeom, Kyeong-Min; Song, Young-Gi; Yoo, Jeong-Ju; Kim, Sang Gyune; Kim, Young Seok
- Abstract
Background and Objectives: Variceal bleeding (VB) is the most concerning condition that is difficult to treat after atezolizumab/bevacizumab in patients with advanced hepatocellular carcinoma (HCC). Materials and Methods: We would like to introduce the cases of two patients who underwent bevacizumab reduction or discontinuation when VB occurred after atezolizumab/bevacizumab. Results: VB occurred in two patients who showed good tumor response after atezolizumab/bevacizumab treatment, and all VBs were successfully treated with endoscopic variceal ligations. In the first patient, VB did not occur as the tumor response decreased after a 50% reduction in bevacizumab. In the second patient, VB occurred again after a 50% bevacizumab reduction, so bevacizumab was discontinued and treatment with atezolizumab alone has been successfully maintained. Conclusions: Accordingly, we would like to suggest that considering bevacizumab dose reduction instead of changing to tyrosine kinase inhibitor may be a good clinical choice in atezolizumab/bevacizumab patients who develop VB.
- Subjects
BEVACIZUMAB; ATEZOLIZUMAB; HEPATOCELLULAR carcinoma; PROTEIN-tyrosine kinase inhibitors; HEMORRHAGE; ESOPHAGEAL varices
- Publication
Medicina (1010660X), 2024, Vol 60, Issue 1, p157
- ISSN
1010-660X
- Publication type
Case Study
- DOI
10.3390/medicina60010157